Clinical Trials

Find a Doctor Our Locations Awards and Accreditation

Home › Research › Trials

Randomized, open-label study of oral ABL001 versus bosutinib in patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies

A Phase 1 Dose-Escalation and Cohort-Expansion Study of the Heat Shock Protein 90 Inhibitor, LAM-003, in Patients with Acute Myeloid Leukemia

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Phase 1, Open-Label, Dose-Finding Study of CC-90009, A Novel Cereblon E3 Ligase Modulating Drug, In Subjects with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 3, Double-Blind, Placebo-Controlled Study Of Quizartinib (AC220) In Combination with Induction and Consolidation Chemotherapy, and Maintenance Therapy in Patients 18 To 70 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy